Danmei Pang

P.R. China
Foshan, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications

Real-world outcomes of trastuzumab deruxtecan in HR-negative HER2-low metastatic breast cancer.

Real-world outcomes of trastuzumab deruxtecan in HR-negative HER2-low metastatic breast cancer.

Journal: NPJ breast cancer
Published: July 21, 2025

HDAC inhibitor tucidinostat and metronomic capecitabine plus endocrine therapy for patients with HR-positive HER2-negative advanced breast cancer after CDK4/6 inhibitors treatment: clinical findings and exploratory circulating tumor cell and ctDNA biomarker analyses of a multicenter, phase 2 study (SYSUCC-020 trial).

HDAC inhibitor tucidinostat and metronomic capecitabine plus endocrine therapy for patients with HR-positive HER2-negative advanced breast cancer after CDK4/6 inhibitors treatment: clinical findings and exploratory circulating tumor cell and ctDNA biomarker analyses of a multicenter, phase 2 study (SYSUCC-020 trial).

Journal: Signal transduction and targeted therapy
Published: May 27, 2025

A plain language summary of results from the TORCHLIGHT trial of toripalimab plus chemotherapy for metastatic or recurrent triple-negative breast cancer.

A plain language summary of results from the TORCHLIGHT trial of toripalimab plus chemotherapy for metastatic or recurrent triple-negative breast cancer.

Journal: Future oncology (London, England)
Published: December 04, 2024

Capivasertib plus fulvestrant in patients with HR-positive/HER2-negative advanced breast cancer: phase 3 CAPItello-291 study extended Chinese cohort.

Capivasertib plus fulvestrant in patients with HR-positive/HER2-negative advanced breast cancer: phase 3 CAPItello-291 study extended Chinese cohort.

Journal: Nature communications
Published: July 12, 2024

Anlotinib as a maintenance treatment for advanced soft tissue sarcoma after first-line chemotherapy (ALTER-S006): a multicentre, open-label, single-arm, phase 2 trial.

Anlotinib as a maintenance treatment for advanced soft tissue sarcoma after first-line chemotherapy (ALTER-S006): a multicentre, open-label, single-arm, phase 2 trial.

Journal: EClinicalMedicine
Published: June 11, 2023

Toripalimab plus nab-paclitaxel in metastatic or recurrent triple-negative breast cancer: a randomized phase 3 trial.

Toripalimab plus nab-paclitaxel in metastatic or recurrent triple-negative breast cancer: a randomized phase 3 trial.

Journal: Nature medicine
Published: June 09, 2023

Survival and clinicopathological significance of blood vessel invasion in operable breast cancer: a systematic review and meta-analysis.

Survival and clinicopathological significance of blood vessel invasion in operable breast cancer: a systematic review and meta-analysis.

Journal: Japanese journal of clinical oncology
Published: December 22, 2021

Development and validation of a nomogram in survival prediction among advanced breast cancer patients.

Development and validation of a nomogram in survival prediction among advanced breast cancer patients.

Journal: Annals of translational medicine
Published: December 14, 2020

A Phase II Study of Fulvestrant 500 mg as Maintenance Therapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Patients with Advanced Breast Cancer After First-Line Chemotherapy.

A Phase II Study of Fulvestrant 500 mg as Maintenance Therapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Patients with Advanced Breast Cancer After First-Line Chemotherapy.

Journal: The oncologist
Published: August 21, 2020

Comparison of regulatory networks of E74-like factor 1 and cold-shock domain-containing E1 in breast cancer cell lines using ChIP datasets.

Comparison of regulatory networks of E74-like factor 1 and cold-shock domain-containing E1 in breast cancer cell lines using ChIP datasets.

Journal: Experimental and therapeutic medicine
Published: September 30, 2019

Germline mutation landscape of Chinese patients with familial breast/ovarian cancer in a panel of 22 susceptibility genes.

Germline mutation landscape of Chinese patients with familial breast/ovarian cancer in a panel of 22 susceptibility genes.

Journal: Cancer medicine
Published: December 20, 2018

The novel long non‑coding RNA PRNCR1‑2 is involved in breast cancer cell proliferation, migration, invasion and cell cycle progression.

The novel long non‑coding RNA PRNCR1‑2 is involved in breast cancer cell proliferation, migration, invasion and cell cycle progression.

Journal: Molecular medicine reports
Published: May 08, 2018
Showing 1-12 of 14

Last Updated: 09/26/2026